The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| CORT | +42.03% | +293.25% | +31.5% | +481% |
| S&P | +18.54% | +92.9% | +14.04% | +500% |
Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development and commercialization of medications to treat severe metabolic, oncologic and psychiatric disorders. It focuses on the development of drugs for disorders that are associated with a steroid hormone called cortisol. Its products include korlym and korlym support. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Menlo Park, CA.
Making medicines is a more reliable path to share price appreciation than memes.
Investors may be looking for a bargain after the company was hit with bad news this week.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $194.43M | 18.7% |
| Gross Profit | $191.00M | 18.4% |
| Gross Margin | 98.23% | -0.2% |
| Market Cap | $7.78B | 130.1% |
| Market Cap / Employee | $15.57M | 0.0% |
| Employees | 500 | 42.0% |
| Net Income | $34.61M | -1.4% |
| EBITDA | $27.14M | -24.3% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $102.75M | -20.1% |
| Accounts Receivable | $64.57M | 19.9% |
| Inventory | 12.3 | 47.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $5.59M | -0.7% |
| Short Term Debt | $1.02M | 2211.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 17.41% | -2.8% |
| Return On Invested Capital | 22.31% | -1.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $43.88M | 7.6% |
| Operating Free Cash Flow | $43.94M | 6.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 36.81 | 40.86 | 99.14 | 65.32 | 126.66% |
| Price to Book | 7.59 | 8.26 | 17.67 | 11.38 | 84.55% |
| Price to Sales | 8.37 | 8.84 | 19.97 | 12.35 | 94.63% |
| Price to Tangible Book Value | 7.59 | 8.26 | 17.67 | 11.38 | 84.55% |
| Price to Free Cash Flow TTM | 36.91 | 30.47 | 77.25 | 49.06 | 67.32% |
| Enterprise Value to EBITDA | 103.82 | 217.43 | 3447.60 | 313.44 | 257.07% |
| Free Cash Flow Yield | 2.7% | 3.3% | 1.3% | 2.0% | -40.24% |
| Return on Equity | 25.5% | 23.6% | 21.5% | 21.4% | -12.73% |
| Total Debt | $6.79M | $6.94M | $6.84M | $6.61M | 16.51% |
CORT earnings call for the period ending June 30, 2022.
CORT earnings call for the period ending March 31, 2022.
CORT earnings call for the period ending December 31, 2021.
CORT earnings call for the period ending September 30, 2021.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
